Named on one round in the feed.
Since 2025-12-08
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
SanegeneBio Innovative RNAi therapeutics for chronic diseases, targeting autoimmune, cardiovascular, obesity, and metabolic diseases for healthcare providers and researchers. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-12-08 | [ PART ] |
No sector on record.